Floatz logo

Pembrolizumab

Metastatic Colon Cancer

Asha Nayakmonoclonal_antibodyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Metastatic Colon Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Fudan University
Phase 4BBB
Fruquintinib
Peking University
Phase 3BBB
DEXAMETHASONE
Fudan University
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →